The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Kidney Neoplasms , 38 publications
- Carcinoma, Renal Cell , 28 publications
- Nephrectomy , 20 publications
- Prostatic Neoplasms , 17 publications
Research activity
Active clinical trials
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as…
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
93 publications
2022
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
European urology
PubMed • Publisher's site2022
Detection of PD-L1-Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes.
Journal of immunology (Baltimore, Md. : 1950)
PubMed • Publisher's site2022
High Levels of PD-L1+ and Hyal2+ Myeloid-derived Suppressor Cells in Renal Cell Carcinoma.
Journal of kidney cancer and VHL
PubMed • Publisher's site2022
Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Cancers
PubMed • Publisher's site2022
Succinate dehydrogenase deficient renal cell carcinoma: A case report.
Urology case reports
PubMed • Publisher's site